Linked Life Data

20187196

Source:http://linkedlifedata.com/resource/pubmed/id/20187196

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-3-3
pubmed:abstractText
To evaluate in a rat brain glioma model intraindividual tumor enhancement at 1.5 T using gadobutrol (Gadovist), a nonionic, macrocyclic chelate currently in clinical trials in the United States, in comparison with both an ionic macrocyclic chelate, gadoterate meglumine (Dotarem), and an ionic linear chelate, gadopentetate dimeglumine (Magnevist), and to compare the degree of tumor enhancement with gadobutrol at 1.5 and 3 T.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1522-2586
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
549-55
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
pubmed:affiliation
Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany. ulrike.attenberger@medma.uni-heidelberg.de
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Evaluation Studies